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Introduction: High-volume hemofiltration (HVHF) is an attractive therapy for the treatment of septic acute kidney
injury (AKI). Small experimental and uncontrolled studies have suggested hemodynamic and survival benefits at
higher doses of HVHF than those used for the high-intensity arms of the RENAL and ATN studies. Our aim was to
evaluate the effects of high-volume hemofiltration (HVHF) compared with standard-volume hemofiltration (SVHF)
for septic AKI.
Methods: A systematic review and meta-analysis of publications between 1966 and 2013 was performed. The review
was limited to randomized-controlled trials that compared HVHF (effluent rate greater than 50 ml/kg per hour) versus
SVHF in the treatment of sepsis and septic shock. The primary outcome assessed was 28-day mortality. Other outcomes
assessed were recovery of kidney function, lengths of ICU and hospital stays, vasopressor dose reduction, and adverse
events.
Results: Four trials, including 470 total participants, were included. Pooled analysis for 28-day mortality did not show
any meaningful difference between HVHF compared with SVHF (OR, 0.76; 95% CI, 0.45 to 1.29). No included
studies reported statistically significant differences between groups for any of the secondary outcomes. Adverse
events, including hypophosphatemia and hypokalemia, were more commonly observed in HVHF-treated patients,
although reporting was inconsistent across studies.
Conclusions: Insufficient evidence exists of a therapeutic benefit for routine use of HVHF for septic AKI, other than on
an experimental basis. Given the logistic challenges related to patient recruitment along with an incomplete
understanding of the biologic mechanisms by which HVHF may modify outcomes, further trials should focus on
alternative extracorporeal therapies as an adjuvant therapy for septic AKI rather than HVHF.Introduction
Sepsis is a common cause of critical illness and the leading
cause of death for patients admitted to the intensive care
unit (ICU) [1]. It has been theorized that the removal of
inflammatory mediators and/or bacterial toxins from the
bloodstream could result in a beneficial downregulation of
an overactive immune response that mediates end-organ
damage in patients with septic shock [2-4]. As such, vari-
ous forms of extracorporeal blood purification have been
studied as therapeutic interventions to improve the poor
outcome associated with septic shock [5,6].* Correspondence: bagshaw@ualberta.ca
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reproduction in any medium, provided the orThe definition of what constitutes high volume in
HVHF remains unclear [6,7]. Based on the results of two
large randomized-controlled trials (RCTs) [8,9] and sub-
sequent systematic reviews [10,11], the adequate dose of
hemofiltration treatment for acute kidney injury (AKI)
(that is, the renal dose) has been defined as an effluent
rate between 25 and 30 ml/kg/hour [12]. This is consistent
with HVHF being defined by an effluent rate exceeding
35 ml/kg/hour [13]. However, early experimental studies
found significant hemodynamic improvements only at
markedly higher effluent rates [14,15], suggesting that a
cut-off of 35 ml/kg/hour may be too low [7]. Evidence
supporting this notion was described in a systematic
review of animal studies showing hemofiltration at “renal-
dose” rates was relatively ineffective for cytokine removal
[5]. Furthermore, in a post hoc analysis, a seminal triald. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ated with a survival benefit for a small subgroup of pa-
tients with septic AKI [16].
To address uncertainty in terms of how best to define
HVHF, a consensus conference was held in Pardubice,
Czech Republic, the results of which were reported in a
consensus statement [17]. HVHF was defined as con-
tinuous high-volume treatment with an effluent rate of
50 to 70 ml/kg/hour (for 24 hours per day) or intermit-
tent very high-volume treatment with an effluent rate of
100 to 120 ml/kg/hour for a 4 to 8-hour period followed
by conventional renal-dose hemofiltration. This has sub-
sequently been referred by some experts as the Pardu-
bice consensus definition of HVHF [17].
Although the use of HVHF to treat septic AKI may hold
promise, the initiation of any form of extracorporeal blood
purification involves the risk of mechanical complications
related to insertion of a large-bore dialysis catheter for cen-
tral venous access. Other complications associated with
HVHF may include hemodynamic compromise; nutrient,
vitamin, and trace-metal depletion; and reduction of blood
levels of antibiotics and other medications below the thera-
peutic range; along with technical challenges related to the
time-dependent loss of hemofilter efficiency and bedside
nursing workload [6,17].
Given that any benefit might be seen at higher doses
of hemofiltration, and that the previously mentioned
risks of harm might also be increased, we sought to per-
form a systematic review of randomized controlled trials
that assessed the use of hemofiltration for sepsis at doses
greater than the renal-dose in accordance with the Par-
dubice definition of HVHF.Methods
This study is reported according to Preferred Reporting
Items for Systematic Reviews and Meta-Analyses (PRISMA)
statement recommendations [18]. See Additional file 1 for a
copy of the PRISMA checklist.Search methods for identification of studies
The following databases were electronically searched:
Cochrane Database of Systematic Reviews, DARE (Data-
base of Abstracts of Reviews of Effects), Cochrane Cen-
tral Register of Controlled Trials (CENTRAL), Medline
and Medline in Process (via OVID), and Embase (via
OVID). A search strategy was developed to define key
words for all searches (see Additional file 2 for Medline
search). Abstracts from recent major conferences of lead-
ing nephrology and critical care organizations (American
Society of Nephrology, International Society of Nephrol-
ogy, American Thoracic Society, European Society of Crit-
ical Care Medicine, Society of Critical Care Medicine)
from the past 5 years were also searched for relevantabstracts. The search included articles published on or be-
fore July 5, 2013. There were no language restrictions.
Selection of studies
All citations were initially screened by two authors (EC
and AM) to select articles for full-text review. Any dis-
agreement regarding the final selection of studies for inclu-
sion was resolved by consensus with a third investigator




 Patients admitted to ICU
 Adults age ≥18 years
 Diagnosis of sepsis/septic shock
 Report specifically on outcomes of comparator/
control group
 Treatment with HVHF defined according to an
effluent rate of ≥50 ml/kg/hour, continuously, or
intermittent very high-volume treatment with an
effluent rate of 100 to120 ml/kg/hour for a 4- to 8-hour
period followed by conventional renal-dose continuous
renal-replacement therapy (CRRT).
 Reporting of the primary outcome (mortality) for
any time point.
Exclusion criteria
 Observational studies, quasi-randomized or crossover
studies, case reports, case-series, use of historical
controls, review articles
 Neonatal/pediatric population
 Post-cardiac surgery population
Data extraction
Data were independently extracted from full-text articles
by two authors (EC and AM). After extraction, data were
reviewed and compared by EC, with disagreements
solved by consensus.
Definition of end points
The primary end point was mortality (28-day and at any
time). Secondary outcomes considered were recovery of kid-
ney function (that is, dialysis independence), hemodynamic
profile (that is, reduced vasopressor requirements or im-
proved blood pressure), proportion with shock reversal and/
or time to shock reversal, organ-failure burden (for example,
sequential organ failure assessment (SOFA), acute physi-
ology and chronic health evaluation (APACHE) II scores),
and lengths of stay (ICU, hospital). Adverse events that may
be therapy related were also considered as secondary end
points. These included electrolyte, nutrient, vitamin, and
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biotics and other medications below the therapeutic range.
Assessment of methodologic quality
All included studies were assessed by using Jadad scoring
(the Oxford quality scoring system) for clinical trials [19],
which encompasses the reporting of randomization tech-
nique, presence and appropriateness of blinding, and de-
scription of dropouts and withdrawals. In addition, we
considered whether analysis was conducted according to
the “intention-to-treat”, if an a priori defined protocoliza-
tion of interventions and a priori defined primary and sec-
ondary end points.
Statistical analysis
Data analysis was performed by using Review Manager,
version 5.0 (RevMan; The Nordic Cochrane Centre, The
Cochrane Collaboration 2008, Copenhagen, Denmark).
For the outcome of 28-day mortality, data from included
studies was combined by using a random-effects model
expressed as an odds ratio with a 95% confidence
interval. The level of statistical significance was set at
P < 0.05. This analysis was also conducted by using a
fixed-effects model to evaluate for robustness and sus-
ceptibility to outliers. Statistical heterogeneity was
quantified for the pooled result by using the τ2, χ2, orFigure 1 Flow diagram of process for identification of studies. Templa
PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and




Our search of Medline yielded 327 citations; Embase,
545 citations; and Cochrane and DARE databases, 12
citations. The search of conference abstracts identified
five abstracts that were found to be “duplicate” ab-
stracts related to full-text publications. After removing
duplicates (n = 187), the search strategy identified 1,068 ci-
tations. Figure 1 is a flow diagram detailing the process by
which studies were identified.
After initial screening, eight studies were obtained for
full-text review. Of those, four fulfilled eligibility and
were included. Four studies were excluded for the fol-
lowing reasons: one was a cross-over study [20], three
were not RCTs [21,22], and, as previously noted by
Borthwick et al. [23], for one study [24], the mortality
rate quoted was for an unspecified time point, and the
number of deaths did not correspond to reported mor-
tality rates.
Study characteristics and quality
The characteristics and quality assessment of included
studies are detailed in Table 1. The studies by Boussekeyte Modified from: Moher D, Liberati A, Tetzlaff J, Altman DG, The
Meta-Analyses: The PRISMA Statement. PLoS Med 2009, 6: e1000097.
Table 1 Summary of included studies
Study Journal Location Setting Jadad
scalea
Primary end point Follow-up
Boussekey (2008) [25] Intensive Care Medicine France Single-center ICU 3 75% decrease in vasopressor
dose after 24 hours
28 days
Sanchez (2010) [27] Intensive Care Medicine (abstract) Spain Single-center ICU 1 All-cause mortality at 28 days -
Zhang (2012) [28] Nephrology Dialysis
Transplantation
China Single-center ICU 2b All-cause mortality at 28 daysc 90 days
Joannes-Boyau
(2013) [26]
Intensive Care Medicine France, Belgium,
the Netherlands
18 ICUs 3 All-cause mortality at 28 days 90 days
aJadad scale for quality appraisal (total possible score, 5) [19].
bNo discussion of dropouts or withdrawals, but none occurred.
cStated primary end point “death from any cause within 28, 60, and 90 days after randomization”.
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[27] assessed HVHF in patients with septic shock and
AKI, whereas the study by Zhang et al. [28] enrolled pa-
tients with severe sepsis and AKI. No included study
was blinded. Three studies were analyzed according to
intention-to-treat, featured a priori-defined protocoliza-
tion of interventions and a priori-defined primary and
secondary end points [25,26,28]; whereas these details
were not described for Sanchez et al. [27]. The study by
Joannes-Boyau et al. was the only multicenter study and
used block computer randomization [26].
Table 2 details the baseline characteristics of study
participants. Details regarding HVHF and SVHF treat-
ment are reported in Table 3. A substantial difference in
the time from ICU admission to enrollment was ob-
served between studies.
Mortality outcomes
No study showed a statistically significant reduction in
mortality for HVHF compared with SVHF. The study
by Boussekey et al. [25] was not designed for mortality
as a primary outcome; however, reported 28-day mor-
tality as a secondary outcome. The other three studies
specified 28-day mortality as a primary outcome [26-28].
For the four included studies, the pooled odds ratio (95%
CI) for 28-day mortality for HVHF compared with SVHF
was 0.76 (95% CI, 0.45 to 1.29; P = 0.31) (Figure 2). NoTable 2 Baseline patient characteristics of included studies






Boussekey (2008) [25] 19a 9 (47) 68 72.5 7 (7
Sanchez (2010) [27] 30 15 (50) 59 (13)
Zhang (2012) [28] 280 141 (50) 57 60 83 (
Joannes-Boyau
(2013) [26]
137b 66 (48) 68 70 68 (
sCr, serum creatinine.
aNumber of patients included for analysis. Number randomized was 20.
bNumber of patients included for analysis. Number randomized was 140.
NR, not reported. NB, For all studies, no statistically significant differences were fou
control groups.significant heterogeneity was observed across studies for
28-day mortality (τ2 = 0.08; χ2 = 4.19 (P = 0.24); І2 = 28.4%).
The studies by Zhang et al. [26] and Joannes-Boyau
et al. [28] also reported 60- and 90-day mortality
[26,28]. In both studies, HVHF had no discernible im-
pact on mortality at 60 or 90 days compared with SVHF.
Secondary outcomes
Vasopressor dose reduction
Boussekey et al. [25] showed more patients who received
HVHF (eight of nine) had a 75% reduction in norepin-
ephrine dose within 24 hours compared with those who
received SVHF (four of 10) (relative risk (RR) 2.22 (95%
CI, 1.01 to 4.51) [25]. The study by Zhang et al. [28]
showed no significant differences in norepinephrine
doses before and after treatment with HVHF or SVHF
[28]. Joannes-Boyau et al. [26] found no effect of HVHF
on vasopressor dependency with an RR (for the Log
Vasopressor Dependency Index) of 1.005 (95% CI, 0.99
to 1.02) [26]. The heterogeneous measures used to de-
termine vasopressor reduction across studies did not
allow pooled analysis.
Recovery of kidney function
Boussekey et al. [25] reported all surviving patients had
recovery of kidney function by ICU discharge. The stud-
ies by Zhang et al. [25] and Joannes-Boyau et al. [28]ale gender:
(n, %)




F Control HVHF Control HVHF Control HVHF Control
8) 8 (80) 205 191 31 33.5 68 67
21 (70) - - - - - -
59) 89 (64) 248 263 22 23 NR NR
45) 54 (38) 227 210 NR NR 68 64
nd in baseline patient characteristics (as reported earlier) between HVHF and
Table 3 Details of high-volume and standard-volume hemofiltration for included studies








HVHF Control HF HVHF Control HF HVHF Control HF HVHF Control HF
Boussekey (2008) [25] CVVH 65 35 62 32 Not stateda Not stateda 7 6
Sanchez (2010) [27] CVVH 55 35 - - - - 5.7 6.4
Zhang (2012) [28] CVVH 85 50 87.54 49.99 5.4 6.2 9.38 8.88
Joannes-Boyau
(2013) [26]
CVVH 70 35 65.6 33.2 2.4 1.9 6b 7b
CVVH, continuous veno-venous hemofiltration. aBoussekey et al. [25] reported “time from shock to hemofiltration”: 21 hours for HVHF; 15.5 hours for SVHF. bThis
was estimated according to the outcome ”RRT-free days at day 90”.
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survivors with dialysis dependence at 90 days. Zhang et
al. [28] reported no significant difference in dialysis de-
pendence among survivors at 90 days (HVHF, 7% (four
of 57) versus SVHF 10% (five of 51)) [28]. For the study
by Joannes-Boyau et al. (26), no patient of 29 in the
HVHF group and 3% (one of 35) in the SVHF group
were dialysis dependent at 90 days.
Lengths of stay
No study demonstrated significant differences or import-
ant trends in ICU or hospital lengths of stay between
HVHF and SVHF groups, respectively.
Adverse events
Two studies did not describe adverse events [25,27]. In
the study by Zhang et al. [28], adverse events were not
specifically described; however, it was noted that three
patients in the HVHF group and one in the SVHF had
hypothermia, defined as a core temperature <34°C while
receiving CRRT [28]. Associated with this, core temperature
was significantly lower in the HVHF compared with SVHF
group (37.2°C versus 37.9°C; P < 0.001). The authors also de-
scribed that hypophosphatemia occurred more commonly
among HVHF-treated patients (65%) compared with SVHF
(54%); however, hypophosphatemia was not specifically
defined [28].
The study by Joannes-Boyau et al. [26] reported three
adverse events (one acute embolic stroke, one myocar-
dial infarction, and one episode of major postoperative
bleeding). One major adverse event occurred in theFigure 2 Forest plot for odds of 28-day mortality.HVHF and two in the SVHF group, all independently
adjudicated to be unrelated to the study intervention. A
trend toward more hypokalemia in the HVHF-treated
patients was found (30% versus 20%; P = 0.1), whereas
more episodes of hypophosphatemia occurred in HVHF-
treated compared with SVHF-treated patients (HVHF,
97 events, 88% (n = 32) versus SVHF: 43 events, 38%
(n = 34); P < 0.01).
Neither Zhang et al. or Boussekey et al. described
antimicrobial clearance, although Zhang et al. indicated
that the dosing of antibiotics was “adjusted according to
clearance of HVHF during the intervention period”
[25,28]. The study by Joannes-Boyau et al. reported ad-
ministering standard, non-AKI doses of antibiotics in
both arms and that the mean elimination half-life of an-
timicrobials in the HVHF group was significantly shorter
than that in the SVHF group (1.3 to 28.5 hours versus
1.5 to 33.9 hours) [26].
Discussion
A systematic search of the literature for randomized
controlled trials evaluating HVHF, according to the Par-
dubice definition [29], compared with SVHF as adjuvant
therapy for sepsis and septic AKI, found only four eli-
gible studies for analysis. The quality of each study in-
cluded in our review was reasonable, considering the
inherent challenges for blinding an extracorporeal ther-
apy. Our review found that HVHF, compared with
SVHF, had no significant impact on short-term mortal-
ity, kidney recovery, improvement in hemodynamic pro-
file, or reduction in ICU or hospital length-of-stay. In a
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associated with a small but nonsignificant trend toward
benefit compared with SVHF.
The use of an extracorporeal therapy to augment in-
flammatory mediator clearance is conceptually appeal-
ing; however, numerous plausible explanations exist for
the apparent lack of efficacy and potential for harm with
HVHF. First, sepsis and septic AKI are characterized by
an excess production of both pro- and antiinflammatory
mediators [4]. HVHF using conventional hemofilters
may simply be ineffective at providing either sufficient
or sustained mediator clearance to show measurable
benefit [5]. Second, given the critical importance of
timely [30] and appropriate [31] antimicrobial therapy
for the treatment of sepsis, any excess clearance of anti-
microbials with HVHF may contribute to subtherapeutic
plasma concentrations and predispose to treatment fail-
ure or risk of worse outcome [26]. Finally, HVHF is as-
sociated with higher rates of electrolyte abnormalities
(for example, hypophosphatemia, hypokalemia) and ex-
cess micronutrient depletion compared with SVHF,
that may further confound the association between any
therapeutic benefit and outcome [8,26]. Recent data
suggested that the development of hypophosphatemia
during CRRT may portend increased risk for less-
favorable outcomes [32,33]. Finally, although not spe-
cifically discussed in any included study, the bedside
application of HVHF is far more resource intensive for
nurses and may add considerable expense beyond con-
ventional RRT (that is, because of replacement fluid
costs). As such, given the evidence of a lack of efficacy
found in the available higher-quality trials included in
our review, coupled with the concerns for potential ad-
verse effects and added expense, the utility of HVHF
should be questioned as an adjuvant therapy for critic-
ally ill patients with sepsis and septic AKI.
Our review has several important limitations. First,
using the Pardubice definition of HVHF may not have
captured all RCTs evaluating HVHF compared with
SVHF. We also considered that both the ATN and
RENAL trials [8,9] found no evidence of benefit for
higher-intensity RRT (defined as effluent rates of 35 and
40 ml/kg/hr) for the subgroup with sepsis (723 patients
(48%) with severe sepsis in the RENAL trial; 708 patients
[63%] with sepsis in the ATN trial). However, we be-
lieved a focused evaluation of HVHF characterized by ef-
fluent rates exceeding the intervention arms of these
trials was necessary, based on data suggesting that
HVHF may be commonly applied in clinical practice
[34]. Second, studies fulfilling eligibility for our review
were heterogeneous. For example, the control group in
the study by Zhang et al. [28] prescribed a relatively high
intensity of HF (prescribed at 50 ml/kg/hr) that approached
the definition of HVHF, according to the Pardubicedefinition. As such, the authors refer to the higher
dose as being extra-high-volume hemofiltration (EHVHF)
and to the control arm of HVHF. After discussion, we be-
lieved this study fulfilled eligibility based on the rationale
that the prescribed dose for this study was only marginally
lower than the high-intensity arms of the RENAL and
ATN trials, which prescribed a lower effluent dose and did
not show improved outcome [8,9,28]. Similarly, the trials
included in our analysis showed substantial variation in
the timing of initiation of the intervention. Whereas it is
not possible to draw definitive conclusions regarding the
impact of variation on the initiation and outcomes in
these studies, timing of therapy may be an important con-
founder of the association between RRT and outcome, in
particular, renal recovery [35].
Although we focused on RCTs for this analysis, it
should be noted that recent reviews of this subject have
taken a broader approach. As detailed in a recent review
[6], both retrospective [36] and prospective cohort stud-
ies [37-39] have suggested improved 28-day survival
compared with historical controls or survival calculated
from illness-severity scores. Using a definition of HVHF
of ultrafiltration rate ≥35 ml/kg/hr [16] and including
studies with a quasi-randomized design, a recent Cochrane
Review included only three studies (64 participants) [23].
This review included the studies by Boussekey et al. and
Ghani et al. (in which problems were identified with the
reporting of mortality data) [24,25]. Further, the small
crossover trial reported by Cole et al. [20] was included in
their analysis, despite no description of mortality out-
comes. No pooled analysis was performed, and the authors
concluded that the evidence base was “very weak” in “sup-
port [of] the use of HVHF in critically ill patients with se-
vere sepsis/septic shock” [23].
Our review also included the study by Boussekey et
al.; however, it was strengthened by the inclusion of the
three recently reported trials [26-28]. We similarly con-
clude that the evidence base to support routine adjuvant
therapy in septic AKI with HVHF is weak. Unlike previ-
ous reviews on this issue; we further conclude that
HVHF is unlikely to be sufficiently beneficial to justify a
large, resource-intensive randomized controlled trial [6,23].
This may be more relevant, given the recruitment chal-
lenges with an intervention of this nature, as described in
the IVOIRE trial [26]. It could be argued that the benefits
of HVHF compared with SVHF observed in uncontrolled
trials, [36-39] in animal studies [14,40,41] and on surrogate
outcomes [20] provide a basis to merit further RCTs
despite the difficulties in patient recruitment. Given
the dangers of relying on surrogate end points in mak-
ing conclusions about clinical efficacy [42] and the re-
cent history of the failure of surrogate end points in
critical care in particular [43-46], we believe that fur-
ther trials of HVHF compared with SVHF for septic
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we have reviewed herein.
In our opinion, the complexity of the disease process
under study (human sepsis with acute kidney injury) and
the incompletely understood nature of the proposed
therapeutic effect of HVHF [4,47] make it a field of
study particularly vulnerable to reliance on surrogate
end points that may subsequently be proven to be in-
valid [42]. A recent post hoc analysis of a nested cohort
of 115 patients from the RENAL study demonstrated
that those in the higher-intensity arm (40 ml/kg per
hour) had improved blood pressure and decreased vaso-
pressor requirements in the absence of other changes
that might explain the effect, such as acid–base or
temperature differences compared with the control arm
[48]. We agree with the authors’ conclusion that investi-
gation of the mechanism underpinning the hemodynamic
improvement observed might provide insight into future
therapeutic interventions [48].
Finally, we acknowledge that our review is limited by a
paucity of high-quality evidence and only included four
randomized trials, three of which were equivocal. How-
ever, a statistical note describing the trial by Joannes-
Boyau et al. [49] further implied their findings were
likely definitive, despite only achieving 30% of planned
recruitment, given no evidence of any difference in out-
come through 90 days and the low probability that this
finding would change if more participants had been
enrolled.
We suggest that a greater understanding of the bio-
logic mechanisms whereby HVHF may exert a thera-
peutic benefit or alternatively concomitantly contribute
harm should be undertaken before conducting further
large-scale RCTs to assess its utility as an adjuvant ther-
apy in septic AKI. In the meantime, studies evaluating
the efficacy of various specialized extracorporeal tech-
niques (for example, high-cutoff hemofilters, hemoad-
sorption) as adjuvant therapies in sepsis may prove more
promising [29].
Conclusions
A systematic review of the literature included four RCTs
that evaluated the use of HVHF compared with SVHF as
an adjuvant therapy for sepsis. Our review is strength-
ened by the addition of two large recently published
RCTs, including a total of 470 patients for analysis.
Based on our review, insufficient evidence exists to sug-
gest a therapeutic benefit for routine use of HVHF in
sepsis other than on an experimental basis. Importantly,
no study included in our review specifically compared
HVHF with standard “renal-dose” RRT, based on current
best evidence (that is, the control arms of the RENAL
and ATN trials [8,9]). As such, no specific recommenda-
tion regarding the use of HVHF in sepsis can be supportedwith high-quality evidence. Moreover, considering the lo-
gistical challenges related to patient recruitment coupled
with the gaps in our understanding of the biologic mecha-
nisms of how HVHF may improve outcome, further
studies should focus on clarifying these mechanisms,
or future studies should focus on alternative extracor-
poreal therapies as an adjuvant therapy for septic AKI
rather than HVHF [5].Key messages
 Our systematic review recovered only four
reasonable-quality trials for inclusion comparing
HVHF and SVHF.
 HVHF as adjuvant therapy for sepsis and septic AKI,
compared with SVHF, showed no significant impact
on short-term mortality or kidney recovery.
 HVHF as adjuvant therapy for sepsis and septic AKI,
compared with SVHF, was also not associated with
sustained improvement in hemodynamic profile or
reduction in ICU or hospital length-of-stay.
 Based on the findings of our review, no specific
recommendation regarding the routine use of
HVHF in sepsis and septic AKI can be supported.
 Future studies should focus on alternative
extracorporeal therapies as adjuvant therapies for
sepsis and septic AKI rather than HVHF.Additional files
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